When Jessica Landsdown's son, Will, was diagnosed with Niemann Pick Type C, she was willing to go anywhere in order to give her son access to a potentially life saving treatment. In this episode, Jessica shares a mother's story of enrolling her son into two expanded access programs for investigational new drugs. Jessica relays her fears of the possibility of losing access to the only possible treatment and the impact that could have on her son. As you listen to this vulnerable conversation, consider how sponsor companies, investigational sites and the entire drug development industry can better serve vulnerable populations.
